[Translated article] Requirements for Accessing New Dermatology Drugs in Spain: Results of the EQUIDAD Study.

BACKGROUND: Although the Spanish Ministry of Health prepares national therapeutic positioning reports (TPRs) and drug reimbursement policies, each of the country's 17 autonomous communities (ACs) is responsible for health care services and prescription requirements in its territory. The aim of the EQUIDAD study was to describe and explore potential differences in prescription requirements for new dermatology drugs across the autonomous communities. MATERIAL AND METHODS: Cross-sectional study conducted in April and May, 2023. Two dermatologists with management responsibilities from each autonomous community reported on territorial and more local prescription requirements for drugs covered by national TPRs issued between 2016 and 2022. RESULTS: Thirty-three researchers from 17 autonomous communities participated. The data submitted revealed between-community inequities in access to new drugs. Overall, 64.7% of the regions imposed additional prescription requirements to those mentioned in the TPRs for psoriasis. This percentage was lower for atopic dermatitis (35.3%) and melanoma (11.8%). The most common requirement for accessing a new drug was a previous prescription for another drug. Differences and additional requirements were also detected at the local level (i.e., differences between hospitals within the same autonomous community). CONCLUSIONS: Spain's autonomous communities have multiple regional and local prescription requirements that are not aligned with national TPR recommendations. These differences result in inequitable access to new drugs for both patients and practitioners across Spain.

Requirements for Accessing New Dermatology Drugs in Spain: Results of the EQUIDAD Study. / Condicionantes de acceso a nuevos medicamentos dermatológicos en España: resultados del proyecto EQUIDAD.

BACKGROUND: Although the Spanish Ministry of Health prepares national therapeutic positioning reports (TPRs) and drug reimbursement policies, each of the country's 17 autonomous communities (ACs) is responsible for health care services and prescription requirements in its territory. The aim of the EQUIDAD study was to describe and explore potential differences in prescription requirements for new dermatology drugs across the autonomous communities. MATERIAL AND METHODS: Cross-sectional study conducted in April and May, 2023. Two dermatologists with management responsibilities from each autonomous community reported on territorial and more local prescription requirements for drugs covered by national TPRs issued between 2016 and 2022. RESULTS: Thirty-three researchers from 17 autonomous communities participated. The data submitted revealed between-community inequities in access to new drugs. Overall, 64.7% of the regions imposed additional prescription requirements to those mentioned in the TPRs for psoriasis. This percentage was lower for atopic dermatitis (35.3%) and melanoma (11.8%). The most common requirement for accessing a new drug was a previous prescription for another drug. Differences and additional requirements were also detected at the local level (i.e., differences between hospitals within the same autonomous community). CONCLUSIONS: Spain's autonomous communities have multiple regional and local prescription requirements that are not aligned with national TPR recommendations. These differences result in inequitable access to new drugs for both patients and practitioners across Spain.

Adaptación transcultural del cuestionario motion sickness susceptibility questionnaire form short (MSSQ-SHORT) para la población adulta chilena / Cross-cultural adaptation of the motion sickness susceptibility questionnaire form short (MSSQ-SHORT) for the chilean adult population

Resumen Introducción: La cinetosis se relaciona con la presencia de una serie de síntomas que comúnmente son inducidos por situaciones cotidianas de viajes en medios de transporte. Una forma utilizada por décadas para determinar el grado de susceptibilidad a la cinetosis ha sido con la aplicación del cuestionario en su versión acortada Motion Sickness Suscep-tibility-short (MSSQ-short). Objetivo: Adaptar lingüística y transculturalmente al español el cuestionario MSSQ-short. Material y Método: Se llevaron a cabo cuatro etapas: Traducción directa, traducción inversa (retrotraducción), consolidación por un comité de expertos y pretest (aplicabilidad/viabilidad). En la etapa de pre-test 51 personas respondieron el cuestionario. Resultados: La discrepancias encontradas en las primeras etapas fueron resueltas por un tercer traductor, el cual concluyó en un documento final en español que fue analizado y revisado por el comité de expertos. Se determinaron los percentiles del 0 al 100, percentil 50 con 9,0 puntos, percentil 25 con 2,13 puntos y el percentil 75 con 17,4 puntos. La consistencia interna del cuestionario fue de 0,889. Conclusión: La traducción y adaptación transcultural fue aceptada por un comité de expertos y participantes con distintas características demográficas y educacionales. El cuestionario obtuvo buena consistencia interna y resultados concordantes con la versión original.

Abstract Introduction: Motion sickness is related to the presence of a series of symptoms that are typically induced by everyday situations of travel in means of transport. A way used for decades to determine the degree of susceptibility to motion sickness has been with the application of the questionnaire in its shortened version Motion Sickness Susceptibility-short (MSSQ-short). Aim: Linguistically and cross-culturally adapt the MSSQ-short questionnaire to Spanish. Material and Method: Four stages were carried out: direct translation, reverse translation (back translation), consolidation by a committee of experts, and pretest (applicability/feasibility). In the pre-test stage, 51 people answered the questionnaire. Results: The discrepancies found in the early stages were resolved by a third translator, which concluded in a final document in Spanish that was analyzed and reviewed by the expert committee. The percentiles from 0 to 100 were determined, 50th percentile with 9.0 points, 25th percentile with 2.13 points, and 75th percentile with 17.4 points. The internal consistency of the questionnaire was 0.889. Conclusion: The cross-cultural translation and adaptation were accepted by a committee of experts and participants with different demographic and educational characteristics. The questionnaire obtained good internal consistency and results consistent with the original version.

Evaluación electrofisiológica del procesamiento auditivo

Resumen En la actualidad existen distintas herramientas para la evaluación del procesamiento auditivo y sus alteraciones. Además de las pruebas conductuales y de las mediciones electroacústicas, se ha establecido que la batería mínima de evaluación del procesamiento auditivo debe incluir exámenes electrofisiológicos que permitan dar cuenta del estado funcional de las estructuras anatómicas a nivel de tronco cerebral, la corteza auditiva y del sistema nervioso auditivo central en general. Las pruebas electrofisiológicas más descritas en la literatura corresponden a las respuestas auditivas complejas de tronco cerebral, potenciales evocados auditivos de latencia media, potenciales evocados auditivos de latencia tardía, y los potenciales auditivos asociados a eventos como el potencial de disparidad y el P300. A pesar de que diversos organismos internacionales como la American Speech-Language-Hearing Association y la American Academy of Audiology han recomendado su utilización en el proceso diagnóstico del trastorno del procesamiento auditivo y han mencionado su utilidad en la diferenciación de cuadros asociados, no existe evidencia concluyente en relación con sus aplicaciones clínicas. Esto último ha llevado a organizaciones como la British Society of Audiology a poner en duda su verdadera utilidad en estos casos.

Abstract Currently, there are different tools for the assessment of auditory processing and its disorders. In addition to behavioral tests and electroacoustic measurements, it has been established that the minimum battery for auditory processing assessment must include electrophysiological examinations that allow to verify the functional state of anatomical structures at the brainstem, the auditory cortex and, broadly, the central auditory nervous system. In literature, the most described electrophysiological tests correspond to complex auditory brainstem responses, auditory middle latency evoked responses, auditory late latency evoked responses and event related evoked potentials, such as mismatch negativity and P300. Although several international organizations such as the American Speech-Language-Hearing Association and the American Academy of Audiology have recommended its use in the diagnostic process of auditory processing disorder and have mentioned its usefulness in the differentiation of associated conditions, there is no conclusive evidence in relation to its clinical applications. The latter has led organizations such as the British Society of Audiology to question its true usefulness in these cases.

Changing Trends in Drug Prescription and Causes of Treatment Discontinuation of First Biologic Over Ten Years in Psoriasis in the Spanish Biobadaderm Registry. / Cambios en las tendencias de la prescripción y causas de la interrupción en los tratamientos biológicos indicados en la psoriasis durante los primeros 10 años. Datos obtenidos del registro español Biobadaderm.

BACKGROUND AND OBJECTIVES: Current psoriasis guidelines do not usually include recommendations about first line classical or biologic treatment. The objectives of this study were: to describe shifts in the prescription of the first biological treatment, and to compare treatment withdrawal and rates of adverse events over ten years. MATERIAL AND METHODS: Biobadaderm registry was analyzed to describe: first biological prescription in bio-naïve patients, adverse events rate and reasons for drug withdrawal comparing three periods of time (2008-2010, 2011-2014, 2015-2018). RESULTS: Anti-TNF drugs were the most prescribed biological drug from 2008 to 2010. Ustekinumab has become the most prescribed first biologic since 2014. The main reasons for drug discontinuation were adverse events, lack of efficacy and remission. In each period any treatment was less likely to be discontinued due to any of these three reasons comparing to the previous period. CONCLUSIONS: The present study identifies trends in prescription of the first biological antipsoriatic drug in clinical practice from 2008 to 2018. It suggests that we have become more comfortable with the safety profile and more exigent with the efficacy of the drugs.

Mexican oregano (Lippia graveolens) essential oil-in-water emulsions: impact of emulsifier type on the antifungal activity of Candida albicans.

This study examined the impact of emulsifier type on the physicochemical characteristics and antifungal capacity of oregano oil-in-water emulsions: Tween 80, hydroxylated soy lecithin, and gum arabic. GC/MS analysis showed that the major components of the Lippia graveolens essential oils were thymol (31.7%), p-cymene (18.7%), and carvacrol (14.6%). The oil-in-water emulsions were made using ultrasonic technology in which thymol and carvacrol quantities were 12.26-13.67 g/L and 5.6-6.2 g/L, respectively. The droplet size of the emulsions followed the next descendent order: gum arabic > lecithin > T80. The zeta potential of the emulsions favored the stability against coalescence. Finally, the antifungal activity of the emulsions was evaluated, in which, 30 µL/mL of gum arabic or hydroxylated soy lecithin emulsions inhibited the growth of Candida albicans. The result suggests that Mexican oregano essential oil emulsions can be used as an antifungal against of C. albicans.

Hallazgos audiológicos en personas menores de 65 años diagnosticadas con osteoporosis: estudio preliminar / Audiological findings in persons under age of 65 diagnosed with osteoporosis: preliminary study

RESUMEN Introducción: La osteoporosis afecta a 200 millones de personas en el mundo y corresponde a una enfermedad crónica que afecta más a mujeres que a hombres, con una prevalencia en Chile del 1,7% y 0,2%, respectivamente. Debido al gran porcentaje de pacientes que la padecen, se han llevado a cabo diversos estudios sobre los síntomas secundarios que pueden encontrarse en esta patología. En el último tiempo, se ha investigado la osteoporosis como un factor de riesgo para padecer pérdida auditiva. Objetivo: Comparar los resultados de umbrales auditivos aéreos, timpanometria y reflejos acústicos ipsilaterales entre pacientes con osteoporosis y pacientes sin osteoporosis, menores de 65 años sin otra patología de base. Material y método: Estudio preliminar de tipo observacional de caso y controles con alcance exploratorio. Se analizaron 28 oídos de una muestra conformada por un grupo estudio de 7 participantes con osteoporosis y un grupo control de 7 participantes sin osteoporosis. Se evaluó el sistema tímpano osicular con la timpanometria y el umbral del reflejo acústico estapedial ipsilateral, y el nivel auditivo por frecuencia con la audiometria tonal. Resultados: Se observaron diferencias estadísticamente significativas entre ambos grupos en los umbrales auditivos, con predominancia sensorioneural en el grupo estudio, y en los umbrales del reflejo acústico ipsilateral. Conclusión: La osteoporosis podría ser un factor de riesgo para padecer pérdida auditiva del tipo sensorioneural. Es necesario continuar el estudio para obtener resultados con mayor representatividad.

ABSTRACT Introduction: Osteoporosis affects over 200 million people in the world and corresponds to a chronic disease that affects more women than men, with a prevalence in Chile of 1.7% and 0.2% respectively. Due to the large percentage of patients who suffer it, several studies about the secondary symptoms that can be found in this pathology have been carried out. In the last time, osteoporosis has been investigated as a risk factor for hearing loss. Aim: To compare the results of air auditory thresholds, tympanometry, and ipsilateral acoustic reflexes in patients with osteoporosis versus patients without osteoporosis, under 65 years old without another underlying disease. Material and method: Preliminary study of observational type of case and controls with exploratory scope. We analyzed 28 ears of a sample consisted of a group study of 7 participants with osteoporosis and a control group of 7 participants without osteoporosis. The tympanic oscillating system and auditory level of each participant were evaluated with tympanometry, ipsilateral stapedial acoustic reflex threshold and tonal audiometry. Results: Statistically significant differences were observed between both groups in the auditory thresholds with a sensorineural predominance and in the ipsilateral stapedial acoustic reflex thresholds. Conclusions: The osteoporosis could be a risk factor for suffer hearing loss of sensorineural type. It is necessary to continue the study to obtain results with greater representativeness.

Transplantation of Human Neural Progenitor Cells (NPC) into Putamina of Parkinsonian Patients: A Case Series Study, Safety and Efficacy Four Years after Surgery.

Individuals with Parkinson's disease (PD) suffer from motor and mental disturbances due to degeneration of dopaminergic and non-dopaminergic neuronal systems. Although they provide temporary symptom relief, current treatments fail to control motor and non-motor alterations or to arrest disease progression. Aiming to explore safety and possible motor and neuropsychological benefits of a novel strategy to improve the PD condition, a case series study was designed for brain grafting of human neural progenitor cells (NPCs) to a group of eight patients with moderate PD. A NPC line, expressing Oct-4 and Sox-2, was manufactured and characterized. Using stereotactic surgery, NPC suspensions were bilaterally injected into patients' dorsal putamina. Cyclosporine A was given for 10 days prior to surgery and continued for 1 month thereafter. Neurological, neuropsychological, and brain imaging evaluations were performed pre-operatively, 1, 2, and 4 years post-surgery. Seven of eight patients have completed 4-year follow-up. The procedure proved to be safe, with no immune responses against the transplant, and no adverse effects. One year after cell grafting, all but one of the seven patients completing the study showed various degrees of motor improvement, and five of them showed better response to medication. PET imaging showed a trend toward enhanced midbrain dopaminergic activity. By their 4-year evaluation, improvements somewhat decreased but remained better than at baseline. Neuropsychological changes were minor, if at all. The intervention appears to be safe. At 4 years post-transplantation we report that undifferentiated NPCs can be delivered safely by stereotaxis to both putamina of patients with PD without causing adverse effects. In 6/7 patients in OFF condition improvement in UPDRS III was observed. PET functional scans suggest enhanced putaminal dopaminergic neurotransmission that could correlate with improved motor function, and better response to L-DOPA. Patients' neuropsychological scores were unaffected by grafting. Trial Registration: Fetal derived stem cells for Parkinson's disease https://doi.org/10.1186/ISRCTN39104513Reg#ISRCTN39104513.

The utility of patient reported data in a gynecologic oncology clinic.

BACKGROUND: Measuring QoL is essential to the field of gynecologic oncology but there seems to be limited standardized data regarding collecting QoL assessments throughout a patient's cancer treatment especially in non-clinical trial patients. The aim of this study is to explore patient characteristics that may be associated with poor quality of life (QoL) in women with gynecologic cancers at two University of Arizona Cancer Center (UACC) sites. METHODS: A cross-sectional survey was conducted among English speaking women with gynecologic malignancies at the University of Arizona Cancer Centers in Phoenix and Tucson from April 2012 to July 2015. The survey was a paper packet of questions that was distributed to cancer patients at the time of their clinic visit. The packet contained questions on demographic information, treatment, lifestyle characteristics, pelvic pain and Health-related quality of life (HRQoL). Measures included the generic and cancer-specific scores on the Functional Assessment of Cancer Therapy-General (FACT-G) and the Female Genitourinary Pain Index (GUPI). The total scores and subdomains were compared with descriptive variables (age, body mass index (BMI), diet, exercise, disease status, treatment and support group attendance) using Cronbach alpha (α), Spearman rank correlations (ρ), and Holm's Bonferroni method. RESULTS: One-hundred and forty-nine women completed the survey; 55% (N = 81) were older than 60 years, 38% (N = 45) were obese (BMI > 30), 46% (N = 66) exercised daily, and 84% (N = 111) ate one or more daily serving of fruit and vegetables. Women in remission, those who exercised daily and ate fruits/vegetables were less likely to have their symptoms impact their QoL. Younger women were more likely to report genitourinary issues (p = - 0.22) and overall problems with QoL (p = - 0.29) than older women. Among FACT-G support group responses, we found those that did not attend support groups had a significantly higher emotional wellbeing (p = 0.05). CONCLUSIONS: This study identified potential areas of clinical focus, which aid in understanding our approach to caring for gynecologic cancer patients and improvement of their HRQoL. We identified that age, pelvic pain, and lifestyle characteristics have indicators to poor QoL in women with gynecologic cancers. In this population, younger women and those with pelvic pain complaints, poor diet and exercise habits should be targeted early for supportive care interventions to improve QoL throughout both treatment and survivorship.

Position statement for the management of comorbidities in psoriasis.

BACKGROUND: The association between psoriasis and some diseases has become relevant in recent years. Providing appropriate management of psoriasis from an early stage requires prompt diagnosis and treatment of concomitant diseases and to prevent any potential comorbidity. This approach should consider the adverse events of the drugs used to treat psoriasis potentially related to the onset of comorbidities. OBJECTIVE: To provide the dermatologist with an accurate and friendly tool for systematizing the diagnosis of psoriasis-associated comorbidities, which generally escapes the scope of the dermatology setting, and to facilitate decision-making about the referral and treatment of patients with comorbidities. METHODS: These position statement recommendations were developed by a working group composed of ten experts (four dermatologists, one cardiologist, one rheumatologist, one gastroenterologist, one nephrologist, one endocrinologist and one psychiatrist) and two health services researchers. The expert group selected the psoriasis comorbidities considered according to their relevance in the dermatology setting. The recommendations on diagnostic criteria are based on the current clinical practice guidelines for each of the comorbidities. The information regarding the repercussion of psoriasis medical treatments on associated comorbid diseases was obtained from the summary of product characteristics of each drug. RESULTS: Recommendations were developed to detect and refer the following psoriasis comorbidities: psoriatic arthritis, cardiovascular risk factors (diabetes, dyslipidaemia, obesity, hypertension and metabolic syndrome), non-alcoholic fatty liver disease, inflammatory bowel disease, kidney disease and psychological disorders (anxiety and depression). In addition, alcohol consumption and tobacco consumption were included. The tables and figures are precise, easy-to-use tools to systematize the diagnosis of comorbidities in patients with psoriasis and facilitate the decision-making process regarding referral and treatment of patients with an associated disease. CONCLUSION: The application of these position statement recommendations will facilitate the dermatologist practice, and benefit psoriasis patients' health and quality of life.

Perfil clínico funcional de pacientes con artritis reumatoide derivados a Fisiatría en control en Centro Reumatólogico Avanzado (CREA) del Hospital Clínico Universidad de Chile / Functional clinical profile of patients with Rheumatoid arthritis derived to Physiatry in control at Centro Reumatólogico Avanzado (CREA) of Hospital Clínico Universidad de Chile

Rheumatoid arthritis (RA) is a systemic inflammatory disease that primarily affects the joints causing varying degrees of disability. Non-pharmacological management is increasing evidence of its usefulness impacting functionality. Objectives: To characterize the clinical / functional profile of patients with rheumatoid arthritis derived physiatrist assessment in the Clinical Hospital University of Chile. Methods: We reviewed the clinical records of patients with RA derivatives Physical Medicine, extraction demographics, medical history, physical examination and functionality. Statisticians analysis of central tendency, dispersion, absolute and relative frequencies. Results: 85 medical records were analyzed. 88.2% were women with an average age of 54.05 ± 11.42 years. 38.8% have at least one comorbidity. 34.1% of patients takes between 6 and 15 years of disease. The average drug related AR is 5.6 per patient, being more Disease Modifying Antirheumatic Drugs (DMARDs) found. 35.2% presented falls in the past year. Pain is a symptom found in the history and physical examination with a VAE (venous air embolism) 4.4 ± 2.43 at the time of consultation and 6.7 ± 3.3 in crisis. 20% received kinesic therapy and only 7% occupational therapy. 45.3% of patients having a value of HAQ (health assesment questionnaire) who scored as moderate disability, even if their selfperception of independence reaches 65.9%. Conclusion: The analysis allows us to perform a demographic, clinical and functional profile that allows us to guide rehabilitation actions. (AU)

Prueba de patrones de frecuencia y patrones de duración: evaluación del ordenamiento auditivo temporal / Frequency pattern and duration pattern test: assessment of auditory temporal ordering

Los aspectos temporales de la audición se consideran unos de los mecanismos claves del procesamiento auditivo, ya que resultarían críticos para el adecuado funcionamiento del resto de los procesos auditivos centrales. El ordenamiento auditivo temporal es una de las cuatro habilidades de los aspectos temporales de la audición y se refiere al procesamiento de dos o más estímulos auditivos según su orden de aparición u ocurrencia en el dominio temporal. Ha sido uno de los procesos más ampliamente estudiados debido a sus implicancias en el resto de las habilidades auditivas, así como también en numerosas actividades de la vida diaria, incluyendo la percepción y la discriminación de los sonidos del habla. Históricamente se han utilizado dos pruebas para evaluarlo: la prueba de patrones de frecuencia y la prueba de patrones de duración. Ambas pruebas cuentan con buena sensibilidad y especificidad para detectar lesiones del sistema nervioso auditivo central, incluyendo el hemisferio derecho, izquierdo y cuerpo calloso. En la actualidad, ambas pruebas son utilizadas con frecuencia debido a su eficiencia, su facilidad para ser administrada y la disponibilidad de valores normativos para un amplio rango de población. Se recomienda ampliamente su utilización en la práctica clínica considerando la obtención de valores normativos locales.

The temporal aspects of audition are considered one of the key mechanisms of auditory processing, as they would be critical for the proper functioning of the rest of the central auditory processes. The auditory temporal ordering is referred to one of the four skills of the temporal aspects of audition and refers to the processing of two or more auditory stimuli in their order of appearance or occurrence in the time domain. It has been one of the most widely studied processes due to its implications for the rest of listening skills, as well as in numerous activities of daily life, including perception and discrimination of speech sounds. Historically, two test has been used to evaluate: the frequency pattern and duration pattern tests. Both tests have good sensitivity and specificity to detect lesions at the central auditory nervous system, such as right and left hemisphere and corpus callosum dysfunctions. Currently, both tests are commonly used clinically due to its efficiency, ease of administration and the availability of normative data in wide range of population. Their use is strongly recommended in clinical practice considering obtaining local normative values.

Clinical, Diagnostic, and Therapeutic Implications in Psoriasis Associated With Cardiovascular Disease. / Implicaciones clínicas, diagnósticas y terapéuticas de la psoriasis y enfermedad cardiovascular.

In recent years the concept of psoriasis as a systemic disease has gained acceptance due to its association with numerous comorbid conditions, particularly atherosclerosis and cardiovascular disease. Several studies have shown that patients with psoriasis, especially younger patients and those with more severe forms of psoriasis or with psoriatic arthritis, have a higher prevalence of risk factors and metabolic syndrome, as well as an increased risk of major cardiovascular events such as myocardial infarction, cerebrovascular disease, and peripheral arterial disease. Furthermore, it remains unclear which of the current treatments might be more effective in reducing cardiovascular risk in these patients. It is therefore important for dermatologists to be aware of this increased risk, to be able to detect modifiable risk factors early and, when appropriate, refer patients to other specialists for the prevention of major cardiovascular events.

Reliability of the MDi Psoriasis® Application to Aid Therapeutic Decision-Making in Psoriasis. / Fiabilidad de una aplicación de ayuda a la toma de decisiones terapéuticas en el paciente con psoriasis (MDi Psoriasis®).

BACKGROUND: Therapeutic decisions in psoriasis are influenced by disease factors (e.g., severity or location), comorbidity, and demographic and clinical features. OBJECTIVE: We aimed to assess the reliability of a mobile telephone application (MDi-Psoriasis) designed to help the dermatologist make decisions on how to treat patients with moderate to severe psoriasis. METHOD: We analyzed interobserver agreement between the advice given by an expert panel and the recommendations of the MDi-Psoriasis application in 10 complex cases of moderate to severe psoriasis. The experts were asked their opinion on which treatments were most appropriate, possible, or inappropriate. Data from the same 10 cases were entered into the MDi-Psoriasis application. Agreement was analyzed in 3 ways: paired interobserver concordance (Cohen's κ), multiple interobserver concordance (Fleiss's κ), and percent agreement between recommendations. RESULTS: The mean percent agreement between the total of 1210 observations was 51.3% (95% CI, 48.5-54.1%). Cohen's κ statistic was 0.29 and Fleiss's κ was 0.28. Mean agreement between pairs of human observers only, excluding the MDi-Psoriasis recommendations, was 50.5% (95% CI, 47.6-53.5%). Paired agreement between the recommendations of the MDi-Psoriasis tool and the majority opinion of the expert panel (Cohen's κ) was 0.44 (68.2% agreement). CONCLUSIONS: The MDi-Psoriasis tool can generate recommendations that are comparable to those of experts in psoriasis.

Comparison of phenotype, comorbidities, therapy and adverse events between psoriatic patients with and without psoriatic arthritis. Biobadaderm registry.

BACKGROUND: There are a limited number of studies comparing psoriasis patients without psoriatic arthritis (PsA) to those with arthritis. Previous results are controversial. OBJECTIVES: To perform a comparative analysis of the phenotype, baseline comorbidities, therapeutic profile and incidence of adverse events (particularly overall adverse events, infections and infestations, malignancies and psychiatric disorders) among psoriatic patients with/without PsA. METHODS: All the patients on the Biobadaderm registry, a prospective inception cohort of psoriasis patients on systemic therapy, were included. Patients were divided into two groups: those with psoriasis without arthritis at the time of entry into the cohort (Pso group) and those with psoriasis and psoriatic arthritis (PsA group) at entry. Patients were followed until the censorship date (last visit in a lost-to-follow-up patient, or 10 November 2015, whichever occurred first). We excluded all the patients who developed any kind of signs and/or symptoms of joint involvement during the follow-up. A descriptive analysis was performed. We estimated incidence ratios (IRR) of adverse events during systemic treatment using a mixed-effects Poisson regression. RESULTS: We included 2120 patients: 1871 (88%) patients with psoriasis without arthritis and 249 (12%) with psoriasis and PsA. The follow-up time was 5020 patients-year in the Pso group and 762 patients-year in the PsA group. Patients with PsA had more comorbidities, particularly hypertension and liver disease; used a higher number of systemic therapies, particularly anti-TNFα drugs and combination therapy; and presented more adverse events (IRR adjusted = 1.29; 95% CI: [1.05-1.58]), particularly serious adverse events (IRR adjusted = 1.51; 95% CI: [1.01-2.26]) and infections/infestations (IRR adjusted = 1.88; 95% CI: [1.27-2.79]), independently of the associated comorbidities and present/past therapies. CONCLUSIONS: Given the differences between patients with psoriasis alone or with psoriasis associated with PsA, patients with psoriasis and PsA should be followed and managed more closely and with specific attention.

Management of Biologic Therapy in Moderate to Severe Psoriasis in Surgical Patients: Data From the Spanish Biobadaderm Registry. / Manejo de los tratamientos biológicos en pacientes con psoriasis moderada-grave sometidos a intervenciones quirúrgicas en el registro español Biobadaderm.

BACKGROUND AND OBJECTIVE: We now have considerable experience in the use of biologic agents to treat psoriasis, but doubts about management arise in certain clinical settings. Surgery is one of them. Although treatment guidelines advise that biologics be suspended before major surgery, data about actual clinical practices and associated complications are lacking. We aimed to analyze current practice in the clinical management of these cases. METHODS: Retrospective study of cases in the Biobadaderm database. We analyzed the management of biologic therapy in patients with psoriasis who underwent surgical procedures. RESULTS: Forty-eight of the 2113 patients registered in Biobadaderm underwent surgery. The largest percentage of procedures (31%) involved skin lesions. Biologic treatment was interrupted in 42% of the cases. No postsurgical complications were significantly related to treatment interruption. Likewise we detected no associations between treatment interruption and other variables, such as sex, age, or duration or severity of psoriasis. CONCLUSION: Continuity of biologic treatment and the risk of postsurgical complications were not associated in this study, although conclusions are limited by the small sample size.

Comparación de las amplitudes y latencias de la onda V del potencial evocado auditivo de tronco cerebral obtenidas a través de estímulos clic y CE-Chirp® / Comparison of brainstem auditory evoked potential wave V amplitudes and latencies obtained through click and CE-Chirp® stimuli

Introducción: El potencial evocado auditivo de tronco cerebral (PEATC) se ha convertido en un procedimiento estándar dentro de la evaluación audiológica. Durante décadas, el estímulo más utilizado ha sido el clic, sin embargo, últimamente se ha propuesto la utilización de estímulos de frecuencia modulada (chirp) para obtener resultados más eficientes. Objetivo: Comparar las amplitudes y las latencias de la onda V del PEATC obtenidas a través de estímulos clic y CE-Chirp® a distintas intensidades. Material y método: Se realizó un estudio de tipo cuantitativo, no experimental, transversal y descriptivo en 17 sujetos a los que se evaluó con un PEATC utilizando estímulos clic y CE-Chirp®. Resultados: Se obtuvieron mayores amplitudes de onda Vpara estímulos CE-Chirp® que para clic, en todas las intensidades evaluadas (80, 60, 40,30 y 20 dBnHL). Se obtuvieron menores latencias en la onda Vpara estímulos CE-Chirp® solo a 80 y 60 dBnHL, mientras que en el resto de las intensidades se obtuvo menores latencias con estímulos clic. Conclusiones: Existen diferencias significativas entre las latencias y amplitudes de la onda V obtenidas con estímulos clic y CE-Chirp®. Mientras los estímulos CE-Chirp® aportan en rapidez en el examen y en la búsqueda del umbral electrofisiológico más preciso, los estímulos clic serían los adecuados al momento de realizar un estudio de topodiagnóstico.

Introduction: The auditory brainstem response (ABR) has become a standard procedure in the audiological evaluation. For decades the most widely used stimulus was the click, but recently the use of chirp stimulus has been proposed for obtain more efficient results. Aim: To compare the amplitudes and latencies of wave V of ABR obtained through click and CE-Chirp® stimuli at different intensities. Material and method: A quantitative, not experimental, transversal and descriptive study was conducted with 17 subjects who were evaluated with ABR using click and CE-Chirp® stimuli. Results: Wave V larger amplitudes were verified for stimulus CE-Chirp®, in all the evaluated intensities (80, 60, 40, 30 and 20 dBnHL). Shorter latencies of wave V were obtained for CE-Chirp® stimuli only at 80 and 60 dBnHL, while it was found that the remaining intensities showed lower latencies with click stimuli. Conclusions: There are significant differences between latencies and amplitudes of the wave V obtained with CE-Chirp® and click stimuli. While the CE-Chirp® stimuli provides faster results for most accurate electrophysiological threshold, click stimuli would be appropriate to conduct site of the lesion testing.

Risk of Reactivation of Hepatitis B Virus Infection in Psoriasis Patients Treated With Biologics: A Retrospective Analysis of 20 Cases From the BIOBADADERM Database.

INTRODUCTION AND OBJECTIVES: A 5% risk of reactivation of hepatitis B virus (HBV) infection has been reported in patients with diseases other than psoriasis treated with tumor necrosis factor inhibitors. The aim of this study was to investigate the risk of HBV reactivation in patients with a past history of HBV infection who were receiving biologic therapy for psoriasis. MATERIAL AND METHODS: This was a multicenter study of 20 patients with psoriasis who were treated with at least 1 biologic agent. All the patients had serologic evidence of past HBV infection (positive total hepatitis B core antibody and negative hepatitis B surface antibody). We analyzed the clinical, serological, and liver function variables recorded before, during, and at the end of follow-up. The viral load at the end of follow-up was also analyzed for all patients. RESULTS: None of the patients fulfilled the criteria for HBV reactivation at the end of a median follow-up period of 40 months. Combining our data with data from other studies of psoriasis patients with a past history of HBV infection who were treated with a biologic, we calculated a maximum estimated risk of HBV reactivation for a mean follow-up period of 30 months of 2.7 reactivations per 100 patients. CONCLUSIONS: Biologic therapy did not cause HBV reactivation in our series of patients. Nonetheless, because of the potentially serious complications associated with HBV reactivation, it is important to measure viral load in patients with a history of HBV infection prior to initiation of biologic therapy to rule out occult carriage. These patients should also be monitored regularly in conjunction with a hepatologist.

Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry.

BACKGROUND: Biobadaderm is the Spanish registry of psoriasis patients receiving systemic treatment in clinical practice. OBJECTIVE: To compare the safety of biologics and classic systemic treatment. METHODS: Prospective cohort of patients receiving biologics and classic systemic therapies between 2008 and 2013 in 12 hospitals are included. We registered demographic data, diagnoses, comorbidities, treatments and adverse events (AE). We obtained raw relative risks (RR) for specific AE. Multivariate analysis consisted of Cox models adjusting for age, gender, chronic hepatic disease and previous cancer. RESULTS: A total of 1030 patients received biologics (2061 AE in 3681 person-years), 926 patients classic systemic drugs (1015 AE in 1517 person-years). Ninety-three per cent of AE in both groups were non-serious, 6% serious and 0.003% fatal. The age- and gender-adjusted hazard ratio of AE was lower in the biologics group [hazard ratio 0.6 (95% CI: 0.5-0.7)].We found no differences in rates of serious and mortal AE. Some system organ class AE rates differed between both groups. As limitations: Prescription bias might affect the incidence of AE in both groups. Association of drug and AE was based on timing: associations might not be causal. CONCLUSION: Patients receiving biologics had lower risk of AE. We did not find differences in the risk of serious or fatal AE.

Dolor en artritis reumatoide / Pain in rheumatoid arthritis

Rheumatoid Arthritis (RA) is a systemic inflammatory disease of unknown cause that primarily affects the joints. The joint pain is most often the reason for consultation and main complaint in successive evaluations. The mechanisms of pain in these patients are not entirely clear as inactive stages of the disease, the pain is still a frequent complaint and appears at distant sites to the inflamed joint; it is postulated that there are phenomena of peripheral and central sensitization chronic pain involved would generate; this would require a change in the confrontation of the patient needing a multimodal and comprehensive approach with aggressive pharmacological alternatives that include infiltrations when required and no pharmacological actions such as physiotherapy, occupational therapy and exercise. This is how the early physiatrist assessment appears as an alternative. Then part of the mechanisms involved are reviewed, plus data showing clinical experience when evaluating a cohort of patients diagnosed with RA...